Abstract
1. Abrami,L, et al(1998) The pore-forming toxin proaerolysin is activated by furin. J Biol Chem. 273, 32656-32661. 2. Williams,SA, et al. (2007) A prostate-specific antigenactivated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 99, 376-385. 3. Singh,R, et all. (2007) Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18, 809-816. References PRX302 produced a sustained ≥ 30% improvement in IPSS in the majority of patients at Day 360. A 30% improvement in IPSS is indicative of clinically relevant response. Most of the patients (11/15) receiving ≥1mL/deposit were responders. Overall patients in each study receiving ≥ 1mL per deposit had improvements in IPSS of 10.9s point at day 90 and 10.3 points at day 360. These studies confirm the importance of volume in the efficacy of PRX302
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
